NASDAQ: ABEO - Abeona Therapeutics Inc.

六个月盈利: -4.03%
股息率: 0.00%
部门: Healthcare

促销时间表 Abeona Therapeutics Inc.

先进的时间表 简单图表
Financial Markets by TradingView

关于公司 Abeona Therapeutics Inc.

Abeona Therapeutics Inc., a clinical-stage biopharmaceutical company, develops gene and cell therapies for life-threatening diseases. Its lead clinical program is EB-101, an autologous, engineered cell therapy that is in Phase III clinical trial for recessive dystrophic epidermolysis bullosa. The company also develops ABO-503 for the treatment of X-linked retinoschisis; ABO-504 for the treatment of stargardt disease; and ABO-505 for the treatment of autosomal dominant optic atrophy. In addition, it is developing AAV-based gene therapy through its AIM vector platform programs.

更多详情
The company was formerly known as PlasmaTech Biopharmaceuticals, Inc. and changed its name to Abeona Therapeutics Inc. in June 2015. Abeona Therapeutics Inc. is headquartered in New York, New York.
添加到比较列表
添加到观察列表
添加到投资组合
添加价格通知

IPO date 1980-09-19
ISIN US00289Y2063
Industry Biotechnology
Sector Health Care
Валюта usd
Валюта отчета usd
Див.доход ао 8.55
Дивиденд ао 3706.25
Сайт https://www.abeonatherapeutics.com
Цена ао 5.26
每日价格变化: +1.95% (5.14)
每周价格变化: -9.34% (5.78)
每月价格变化: -3.85% (5.45)
3个月内价格变化: -18% (6.39)
六个月内的价格变化: -4.03% (5.46)
每年价格变化: -32.91% (7.81)
3年内价格变化: +2 093.39% (0.2389)
5年内价格变化: +141.47% (2.17)
10年价格变化: 0% (5.24)
年初以来价格变化: -6.6% (5.61)
所有参数

低估

姓名 意义 年级
P/S 30.36 1
P/BV 7.17 1
P/E 0 0
EV/EBITDA -2.16 0
全部的: 3.5

效率

姓名 意义 年级
ROA, % -84.67 0
ROE, % -365.49 0
全部的: 0

股息

姓名 意义 年级
Div yield, % 0 0
DSI 0.5 5
全部的: 3.78

责任

姓名 意义 年级
Debt/EBITDA -0.12 10
全部的: 10

成长冲动

姓名 意义 年级
盈利能力 Revenue, % 16.67 3
盈利能力 Ebitda, % -24.74 0
盈利能力 EPS, % -93.34 0
全部的: 0.6
更多详情

机构 体积 分享, %
Nantahala Capital Management, LLC 4500504 16.45
Adage Capital Partners GP L.L.C. 3249994 11.88
Millennium Management LLC 1418675 5.19
Vanguard Group Inc 1101131 4.03
Western Standard, LLC 808112 2.95
AIGH Capital Management LLC 787769 2.88
Point72 Asset Management, L.P. 760870 2.78
Ikarian Capital, LLC 600000 2.19
Citigroup Inc. 450347 1.65
J. Goldman & Co., L.P. 429816 1.57

ETF 分享, % 本年盈利能力, % 股息, %
iShares Neuroscience and Healthcare ETF 0.43711 19.72 0.03
iShares Micro-Cap ETF 0.05965 17.09 1.54048



导师 职称 支付 出生年份
Dr. Vishwas Seshadri M.B.A., Ph.D. President, CEO & Director 1.49M 1976 (49 年)
Mr. Brian Kevany Ph.D. Senior VP, CTO & CSO N/A
Mr. Gregory Gin Vice President of Investor Relations & Corporate Communications N/A
Ms. Alison Hardgrove Chief People Officer N/A
Mr. Jon Voss VP & Head of Quality N/A 1960 (65 年)
Dr. Madhav Vasanthavada M.B.A., Ph.D. Senior VP, Chief Commercial Officer & Head of Business Development N/A
Mr. Carl Denny Senior Vice President of Regulatory Affairs N/A
Mr. Joseph Walter Vazzano CPA Chief Financial Officer 920.85k 1984 (41 年)
Dr. Brendan M. O'Malley J.D., Ph.D. Senior VP & General Counsel 1970 (55 年)

地址: United States, New York. NY, 1330 Avenue of the Americas - 在 Google 地图中打开, 打开 Yandex 地图
网站: https://www.abeonatherapeutics.com